155 related articles for article (PubMed ID: 7416617)
1. A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1980 Sep; 122(3):417-24. PubMed ID: 7416617
[TBL] [Abstract][Full Text] [Related]
2. A service programme with a 6-month intensive chemotherapy regimen in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong.
Tubercle; 1983 Dec; 64(4):265-74. PubMed ID: 6659074
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
Am Rev Respir Dis; 1989 Apr; 139(4):871-6. PubMed ID: 2648911
[TBL] [Abstract][Full Text] [Related]
4. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1987 Dec; 136(6):1339-42. PubMed ID: 2891333
[TBL] [Abstract][Full Text] [Related]
5. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
6. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
Tuber Lung Dis; 1992 Feb; 73(1):59-67. PubMed ID: 1326349
[TBL] [Abstract][Full Text] [Related]
7. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Mitchison DA; Nunn AJ
Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
[TBL] [Abstract][Full Text] [Related]
8. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.
Tubercle; 1982 Jun; 63(2):89-98. PubMed ID: 6758252
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.
Lancet; 1981 Jan; 1(8213):171-4. PubMed ID: 6109855
[TBL] [Abstract][Full Text] [Related]
10. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1988 May; 137(5):1147-50. PubMed ID: 2904237
[TBL] [Abstract][Full Text] [Related]
11. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Hong Kong Chest Service/tuberculosis Research Centre, Madras/British Medical Research Council.
Am Rev Respir Dis; 1991 Feb; 143(2):262-7. PubMed ID: 1990938
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
13. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
15. 4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
Chan SL; Wong PC; Tam CM
Tuber Lung Dis; 1994 Aug; 75(4):245-50. PubMed ID: 7949069
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of a 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
Am Rev Respir Dis; 1981 Aug; 124(2):138-42. PubMed ID: 6789733
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
Br J Dis Chest; 1984 Oct; 78(4):330-6. PubMed ID: 6386028
[TBL] [Abstract][Full Text] [Related]
18. [Controlled trial of 6 to 8 month chemotherapeutic regimens in the treatment of pulmonary tuberculosis. A study of Hong Kong Chest Service/British Medical Research Council/].
Aquinas M
Bull Int Union Tuberc; 1978 Dec; 53(4):253. PubMed ID: 387136
[No Abstract] [Full Text] [Related]
19. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
20. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
Shah AR; Agarwal SK; Shah KV
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
